Versant Venture Management, Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$141.4M
Q ending 2026-03-31
Prior quarter
$151.1M
Q ending 2025-12-31
Change
-6.4% QoQ · +134.9% YoY
Positions
8
reported holdings
Largest positions
All 8 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | GLUE | Shares | $52.3M | 3.2M |
| Century Therapeutics, Inc. | IPSC | Shares | $27.5M | 12.2M |
| Lenz Therapeutics, Inc. | LENZ | Shares | $24.3M | 2.7M |
| Jade Biosciences, Inc. | JBIO | Shares | $21.4M | 1.5M |
| Contineum Therapeutics, Inc. | CTNM | Shares | $7.1M | 543K |
| Crispr Therapeutics Ag | Shares | $7.1M | 149K | |
| Skye Bioscience, Inc. | SKYE | Shares | $1.2M | 2.0M |
| Tempest Therapeutics, Inc. | OVASUSD | Shares | $442K | 270K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.